Research question
What is retatrutide?
Retatrutide is a 39-residue lipidated peptide studied in laboratories as a triple agonist at the GLP-1, GIP and glucagon receptors. Published descriptions mention Aib substitutions, an alpha-methyl leucine and a C20 fatty diacid joined through a linker. The development code used in the literature is LY3437943. The CAS registry number is 2381089-83-2. Approximate molecular weight is 4731.33 g/mol and the gross formula quoted on GetReta paperwork is C221H342N46O68.
GetReta sells that compound as a dry research vial, labelled either 30 mg or 40 mg of lyophilised material. The milligram figure is the labelled content of the cake. It is not a dose, not a schedule and not an instruction to prepare a solution for any living subject. There is no marketing authorisation attached to these vials. They are not a medicine and they are not sold for human or veterinary use.
Each dispatched vial carries a lot number that should match the certificate of analysis in the carton. Release testing is HPLC identity and purity at or above 99 percent. A buyer confirms research-use only before payment. The same two vial sizes, at the same prices, are posted across the UK.